ReWalk Robotics reports Q4 EPS (9c) vs (6c) last year

Reports Q4 revenue $2.179M vs $1.242M last year. "The full ReWalk team executed well in the fourth quarter, driving quarterly revenue to the highest level in over five years," remarked Larry Jasinski, Chief Executive Officer of ReWalk. "We demonstrated very balanced performance, with the highest quarterly revenue for exoskeletons in over a year, in both the United States and the European Union, and with record quarterly sales of the MyoCycle functional electronic stimulation bikes. Following our submission of the first case for Medicare coverage and reimbursement of an exoskeleton, we have worked closely with the MAC that is processing the claim to address any questions or supplemental information requests they may have," continued Jasinski. "At the same time, we have made great progress preparing our sales, clinical, and claims processing resources for the increase in patient volumes that we anticipate following prospective successful completion of the first claim. We look forward to continuing our work with the Centers for Medicare and Medicaid Services as we take the next step toward establishing an exoskeleton payment mechanism for Medicare beneficiaries."